Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05724472 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health
A Phase 1 study, sponsored by International AIDS Vaccine Initiative.
- Completed
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
NCT05724472 is a Phase 1 study that has completed, run by International AIDS Vaccine Initiative. The registered enrollment target is 36 participants.
The verdict
NCT05724472, a Phase 1 study, has completed, sponsored by International AIDS Vaccine Initiative.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
Study Summary
A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
Interventions
- DRUG rVSV∆G-SEBOV-GP Vaccine or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2023-06-19 |
| Est. Completion | 2024-01-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05724472
The ClinicalTrials.gov registry entry for NCT05724472 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is International AIDS Vaccine Initiative, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which rVSV∆G-SEBOV-GP Vaccine or Placebo is the first listed.
NCT05724472 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05724472 about?
NCT05724472 is a clinical study titled "Evaluation of Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine in Adults With Good General Health". A Phase 1, Single-blind, Placebo-controlled, Dose-escalation Clinical Trial to Evaluate the Safety and Immunogenicity of rVSVΔG-SEBOV-GP Vaccine at 3 Dose Levels in Adults in Good General Health
What is the current status of trial NCT05724472?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2023-06-19. Estimated completion is 2024-01-09.
What interventions are being tested in trial NCT05724472?
The interventions under investigation include: rVSV∆G-SEBOV-GP Vaccine or Placebo (DRUG).
Who is sponsoring clinical trial NCT05724472?
This trial is sponsored by International AIDS Vaccine Initiative, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.